Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Muhammad Haroon (NPI 1326048927)

Field	Value
Entity Type	Individual
Organization	Muhammad Haroon
Address	450 E 23rd St
City	Fremont
State	NE
ZIP	68025
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 26, 2005

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider’s Medicare business is heavily focused on high-cost immunotherapy agents: J9271 (pembrolizumab) and J9299 (nivolumab) together account for the majority of Medicare revenue, with the top 3 Medicare codes by revenue representing 81.9% of total Medicare revenue. The presence of large claim counts for these two injectable oncology drugs (12.4K and 21.5K claims respectively) indicates the practice is primarily delivering outpatient oncology infusion services rather than a general primary care panel.

Medicare revenue totals $1.4M while there is no Medicaid billing on file, making this provider effectively single-payer (Medicare)-dependent in the available datasets. The absence of Medicaid activity suggests limited engagement with Medicaid populations or billing under other group NPIs for non-Medicare payers, which has implications for payer contracting and risk stratification.

Revenue concentration is extreme: J9271 alone accounts for $533.2K (38.9% of Medicare revenue) and J9299 accounts for $515.5K (37.6%), together making up a very large share of the provider’s Medicare receipts and indicating material dependence on a small set of high-cost drug codes. That concentration signals business risk if utilization patterns, formularies, or site-of-care reimbursement change for these agents.

Competitive standing for the two highest-revenue drug codes is mixed. For J9271 the provider ranks #910 of 1841 nationally (50th percentile), described as typical/unremarkable volume, while for J9299 the provider ranks #146 of 505 (71th percentile), a higher comparative position among a smaller peer set. These ranks suggest the provider is not a national outlier or dominant player in pembrolizumab use but is comparatively more active in nivolumab relative to peers.

Clinical/operational intensity for office-based care appears above average on evaluation-and-management services: 99214 has 816 claims and $73.4K revenue (5.4% of Medicare revenue) and ranks in the 96th percentile nationally as notably above typical volume. This supports the view that the practice combines frequent complex outpatient visits with high-volume infusion services, implying significant non-drug professional services tied to oncology management.

Utilization of supportive and ancillary procedures consistent with oncology infusion is evident: chemotherapy administration codes such as 96413 (345 claims), 96365 (136 claims), 96375 (330 claims), and transfusion or phlebotomy-related codes like 99195 (47 claims) appear in the top codes list. These patterns reinforce that the operation includes on-site infusion and procedure workflow rather than solely prescribing drugs.

Lab and diagnostics appear as recurring revenue contributors consistent with oncology care coordination: flow cytometry-related codes 88185 and 88184 and routine test panels 85025 and 80053 feature on the list, indicating that in-house or closely affiliated lab services are part of the care pathway. Their presence at modest revenue shares (each under 1.1% of Medicare revenue) suggests diagnostics support outpatient oncology treatment but are not the primary revenue drivers.

The provider has been enumerated as an NPI since 2005-07-26 (~21 years), indicating long tenure in the Medicare program. That longevity combined with a drug-centric Medicare revenue profile suggests an established oncology practice with sustained referral patterns focused on immunotherapy administration.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	12,400	$40	$533.2K
J9299	Injection, nivolumab, 1 mg	21,480	$20	$515.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	820	$90	$73.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	27,030	$1	$54K
J1439	Injection, ferric carboxymaltose, 1 mg	42,000	$1	$42K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	350	$100	$33.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	440	$50	$23.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	150	$130	$19.3K
88185	The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with…	820	$20	$14.7K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	1,470	$10	$11.8K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Muhammad Haroon — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	18	30	14,400	$40	$671.6K
J9299	3	10	19,300	$20	$444.5K
J0881	4	10	17,260	$1	$54.5K
J1439	6	30	25,880	$1	$26.4K
96413	20	80	60	$90	$18.2K
99214	123	3,210	110	$70	$14.9K
J3490	14	30	60	$160	$11.3K
88185	3	10	480	$20	$9.1K
99232	687	1,390	80	$60	$8.6K
99213	213	3,220	90	$50	$7.9K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Muhammad Haroon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Timothy Dorius	NE	Internal Medicine Physician	$1M	$0

Nearby Providers

Other providers in the same ZIP code as Muhammad Haroon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Methodist Fremont Health	NE	Rural Acute Care Hospital	$0	$7.9M
Good Neighbor Community Health Center	NE	Federally Qualified Health Center (FQHC)	$0	$4.2M
Pediatric Partners L.L.C.	NE	Family Nurse Practitioner	$0	$2.8M
Methodist Fremont Health	NE	Internal Medicine Physician	$0	$2.7M
Fcd Smiles, PC	NE	Pediatric Dentistry	$0	$1.7M
Albert Behavioral Health LLC	NE	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$1.1M
Fremont Children's Dentistry, LLC	NE	Pediatric Dentistry	$0	$1M
Midwest Anesthesia P.C.	NE	Interventional Pain Medicine Physician	$0	$959.9K
Hand In Hand Therapy LLC	NE	Mental Health Counselor	$0	$874.7K
Me Urgent Care Nebraska, Inc	NE	Urgent Care Clinic/Center	$0	$769.7K

Muhammad Haroon — Billing Profile & Reimbursement Data

Sign up for Muhammad Haroon — Billing Profile & Reimbursement Data policy alerts

Muhammad Haroon — Billing Profile & Reimbursement Data

Sign up for Muhammad Haroon — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References